The Influence of Virtual Reality on Blood Parameters

NCT ID: NCT07042178

Last Updated: 2025-06-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-31

Study Completion Date

2025-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to learn what the impact of exposure to virtual reality content is on the levels of stress-related blood values in healthy volunteers. The main question it aims to answer is:

* To compare the levels of stress-related biomarkers before and after relaxing VR-content (Relax Visit);
* To compare the levels of stress-related biomarkers before and after stress-inducing VR-content (Rollercoaster Visit).

Researchers will compare the Relax and Rollercoaster Visit to see if there is a relationship between the relaxing and stress-inducing VR content on stress-related blood values.

Participants will be asked to watch relaxing or stress-inducing VR content for approximately five minutes. Blood will be withdrawn before and after intervention. After 3-5 weeks the study visit will be repeated using the other VR content.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale: In recent years virtual reality (VR) has become increasingly popular in clinical setting, especially during blood sampling to enhance patient comfort and reduce anxiety. The immersion in a 360° fantasy world contributes to an effective way of distraction. During a medical procedure the patient is allowed to choose a VR interface that corresponds his liking. This can consist in relaxing content, like meditation video's or swimming with dolphins, or stress-inducing content, like a rollercoaster ride. The latter might be problematic due to its potential influence on stress levels. Many laboratory tests, like haematologic and endocrinologic markers can be influenced during an acute stress response. Normally, this physiological process ensures an effective energy metabolism when most needed. However, during a blood withdrawal using stress-inducing VR this is inconvenient as it could theoretically result in elevated or inaccurate laboratory tests. This might lead to additional blood draws, misdiagnoses and potential over- or undertreatment of patients. To the best of our knowledge, no previous research has assessed the accuracy of laboratory tests conducted on blood samples drawn during a VR rollercoaster experience.

Objective: To assess the impact of exposure to relaxing and stress-inducing virtual reality content on the levels of stress-related biomarkers in healthy individuals.

Study design: This is a monocentre pilot cross-over clinical trial. Study participants will be randomly assigned to one of the two arms. These arms determine the order of VR content exposure. The first arm will be exposed to relaxing VR content during the first study visit, during which blood will be drawn before and after the VR experience. Then, after an interval of 3-5 weeks, they will be exposed to stress-inducing VR content and blood will be drawn before and after. The second arm will do the study visits in the opposite order.

Study population: Healthy volunteers between the ages of 18 and 45 years with no medical history on haematologic, endocrinologic or cardiac disorders.

Intervention:

Participants will be exposed to stress-inducing and relaxing VR content during two separate study visits, the Relax Visit and the Rollercoaster Visit. Blood samples will be collected immediately before and after each VR session to measure changes in stress-related biomarkers. Additionally, objective stress levels measured by vital functions (e.g. heart rate, blood pressure) and subjective stress levels measured using a visual analogue scale (VAS) will be collected immediately pre- and post- VR exposure.

Main study parameters/endpoints:

The correlation between stress-related biomarkers (factor VIII activity, vWF ristocetin co-factor activity, copeptin (AVP), prolactin, thyroid stimulating hormone (TSH), cortisol and glucose) before and after relaxing and stress-inducing VR-content.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Participation includes two site visits, with an interval of 3 to 5 weeks. In both visits blood samples will be collected immediately before and after each VR session to measure changes in biomarkers. Additionally, objective stress levels measured by vital functions and subjective stress levels measured using a visual analogue scale will be collected immediately pre- and post- VR exposure. There are no benefits for participants. However, the results of this study may possibly benefit patients with haematological and endocrinological disorders regarding their comfort and anxiety during blood sampling and by reducing unnecessary extra sampling. Furthermore, it may benefit their treatment by optimizing the diagnostic process. Potential risks are the experience of motion-sickness during the VR experience and a blood withdrawal might be experienced as minimally painful for a very short amount of time. However, to minimalize this pain participants will apply a numbing cream one hour before the start of a study visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Virtual Reality Pain Distraction Endocrinology Haematology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A

Arm A receives the Relax visit first and 3-5 weeks later the Rollercoaster Visit.

Group Type EXPERIMENTAL

Meditation video at the beach

Intervention Type OTHER

A virtual reality video consisting of a 5 minute meditation video at te beach.

Rollercoaster video

Intervention Type OTHER

A virtual reality video consisting of a five minute rollercoaster ride.

Arm B

Arm B receives the Rollercoaster Visit first and 3-5 weeks later the Relax Visit.

Group Type EXPERIMENTAL

Meditation video at the beach

Intervention Type OTHER

A virtual reality video consisting of a 5 minute meditation video at te beach.

Rollercoaster video

Intervention Type OTHER

A virtual reality video consisting of a five minute rollercoaster ride.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Meditation video at the beach

A virtual reality video consisting of a 5 minute meditation video at te beach.

Intervention Type OTHER

Rollercoaster video

A virtual reality video consisting of a five minute rollercoaster ride.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 and 45 years old;
* Willing and able to provide written informed consent.

Exclusion Criteria

* A history of motion- or cybersickness;
* Fear of needles;
* Any of the following haematological disorders:

* Congenital or acquired haemophilia A;
* Von Willebrand Disease.
* Any of the following endocrinological disorders:

* Thyroid disorders (e.g. hypo/hyperthyroidism);
* Cushing syndrome;
* Adrenal insufficiency;
* Diabetes mellitus type 1 or 2;
* Central or nephrogenic AVP deficiency.
* A confirmed cardiac disorder;
* All types of epilepsy;
* Every form of medication, except for intermittent use of pain killers but not in the last week (e.g. paracetamol) and an intra-uterine device with or without contraceptive;
* Pregnancy.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Van Creveldkliniek

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Van Creveldkliniek

Center for Benign Hematology, Thrombosis and Haemostasis

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Corien L. Eckhardt, MD PhD

Role: PRINCIPAL_INVESTIGATOR

UMC Utrecht

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Medical Centre Utrecht

Utrecht, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Amber D.W. de Vos, MD

Role: CONTACT

0031887558450

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Amber D.W. de Vos, MD

Role: primary

0031887558450

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL-009813

Identifier Type: REGISTRY

Identifier Source: secondary_id

25U-0212

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Empathy and Virtual Reality (VR)
NCT07314788 NOT_YET_RECRUITING NA
Virtual Reality for Hemophilia
NCT03507582 COMPLETED NA
Virtual Reality and Pain
NCT04351776 COMPLETED NA